Comparing Anika Therapeutics (NASDAQ:ANIK) & AdvanSource Biomaterials Corpration (NASDAQ:ASNB)

Anika Therapeutics (NASDAQ:ANIK) and AdvanSource Biomaterials Corpration (OTCMKTS:ASNB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Volatility & Risk

Anika Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, AdvanSource Biomaterials Corpration has a beta of -2.2, indicating that its share price is 320% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Anika Therapeutics and AdvanSource Biomaterials Corpration, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anika Therapeutics 0 2 2 0 2.50
AdvanSource Biomaterials Corpration 0 0 0 0 N/A

Anika Therapeutics currently has a consensus target price of $38.67, indicating a potential downside of 4.15%. Given Anika Therapeutics’ higher possible upside, equities analysts clearly believe Anika Therapeutics is more favorable than AdvanSource Biomaterials Corpration.

Earnings and Valuation

This table compares Anika Therapeutics and AdvanSource Biomaterials Corpration’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anika Therapeutics $105.56 million 5.43 $18.72 million $1.84 21.92
AdvanSource Biomaterials Corpration $2.92 million 0.68 -$200,000.00 N/A N/A

Anika Therapeutics has higher revenue and earnings than AdvanSource Biomaterials Corpration.


This table compares Anika Therapeutics and AdvanSource Biomaterials Corpration’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anika Therapeutics 27.44% 11.57% 10.68%
AdvanSource Biomaterials Corpration 10.09% -62.83% 11.21%

Insider & Institutional Ownership

93.9% of Anika Therapeutics shares are owned by institutional investors. 3.7% of Anika Therapeutics shares are owned by company insiders. Comparatively, 7.8% of AdvanSource Biomaterials Corpration shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


Anika Therapeutics beats AdvanSource Biomaterials Corpration on 10 of the 12 factors compared between the two stocks.

About Anika Therapeutics

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

About AdvanSource Biomaterials Corpration

AdvanSource Biomaterials Corp. engages in the development of polymer materials which provide critical characteristics in the design and development of medical devices. Its biomaterials are used in devices that are designed for treating a range of anatomical sites and disease states. Its products include ChronoFlex, ChronoSil, HydroMed, HydroThane, and PolyBlend. The company was founded in 1993 and is headquartered in Wilmington, MA.

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with's FREE daily email newsletter.